Encision (ECIA) 10-K 19 Jun 15 2015 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Mar. 31, 2015	31-May-15	Sep. 30, 2014
Document and Entity Information
Entity Registrant Name	ENCISION INC
Entity Central Index Key	930775
Document Type	10-K
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-28
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$4,323,233
Entity Common Stock, Shares Outstanding		10,673,225
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	FY

Balance_Sheets

Balance Sheets (USD $)	Mar. 31, 2015	Mar. 31, 2014
Current assets:
Cash and cash equivalents	$258,656	$1,689,580
Accounts receivable, net of allowance for doubtful accounts of $11,500 at March 31, 2015 and $8,000 at March 31,2014	965,355	863,220
Inventories, net of reserve for obsolescence of $240,000 at March 31, 2015 and $560,000 at March 31, 2014	2,337,654	2,224,228
Prepaid expenses	109,678	65,387
Total current assets	3,671,343	4,842,415
Equipment, at cost:
Furniture, fixtures and equipment	2,961,417	3,641,037
Customer-site equipment	955,969	1,016,265
Accumulated depreciation	-3,140,453	-3,552,079
Equipment, net	776,933	1,105,223
Patents, net of accumulated amortization of $153,494 at March 31, 2015 and $215,969 at March 31, 2014	257,356	248,971
Other assets	20,135	14,127
TOTAL ASSETS	4,725,767	6,210,736
Current liabilities:
Accounts payable	675,411	666,159
Accrued compensation	262,195	264,595
Other accrued liabilities	324,926	408,549
Lease payable - short term		67,057
Deferred rent - short term	30,384	30,384
Total current liabilities	1,292,916	1,436,744
Long-term liabilities
Line of credit	64,000
Lease payable		54,619
Deferred rent	101,280	131,664
Total liabilities	1,458,196	1,623,027
Commitments and contingencies
Shareholders' equity:
Preferred stock, no par value: 10,000,000 shares authorized; none issued and outstanding
Common stock and additional paid-in capital, no par value: 100,000,000 shares authorized; 10,673,225 issued and outstanding at March 31, 2015 and 2014	23,607,688	23,545,080
Accumulated (deficit)	-20,340,117	-18,957,371
Total shareholders' equity	3,267,571	4,587,709
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$4,725,767	$6,210,736

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Mar. 31, 2014
Condensed Balance Sheets
Accounts receivable, allowance for doubtful accounts (in dollars)	$11,500	$8,000
Inventories, reserve for obsolescence (in dollars)	240,000	560,000
Accumulated amortization	$153,494	$215,969
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock and additional paid-in capital, shares authorized	100,000,000	100,000,000
Common stock and additional paid-in capital, shares issued	10,673,225	10,673,225
Common stock and additional paid-in capital, shares outstanding	10,673,225	10,673,225

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenue, Net [Abstract]
NET REVENUE	$9,671,481	$10,546,637
COST OF REVENUE:
Cost of revenue	4,977,258	5,065,670
Impairment cost		1,100,368
Total Cost of Revenue	4,977,258	6,166,038
GROSS PROFIT	4,694,223	4,380,599
OPERATING EXPENSES:
Sales and marketing	2,921,295	2,951,906
General and administrative	1,615,006	1,532,406
Research and development	1,342,411	1,407,337
Total operating expenses	5,878,712	5,891,649
OPERATING INCOME (LOSS)	-1,184,489	-1,511,050
Interest expense, net	-7,381	-37,622
Other income (expense), net	-190,876	-233,006
Interest (expense) and other income, net	-198,257	-270,628
LOSS BEFORE PROVISION FOR INCOME TAXES	-1,382,746	-1,781,678
NET LOSS	($1,382,746)	($1,781,678)
Net loss per share-basic and diluted (in dollars per share)	($0.13)	($0.20)
Weighted Average Number of Shares Outstanding, Basic and Diluted	10,673,225	8,921,669

Statements_of_Shareholders_Equ

Statements of Shareholders' Equity (USD $)	Common Stock and Additional Paid-in Capital	Accumulated Deficit	Total
BALANCES at Mar. 31, 2013	$21,569,993	($17,175,693)	$4,394,300
BALANCES (in shares) at Mar. 31, 2013	8,210,100
Increase (Decrease) in Stockholders' Equity
Net loss		-1,781,678	-1,781,678
Compensation expense related to stock options	64,518		64,518
Issuance of common stock at $0.80 per share, net of direct offering costs of $59,931	1,910,569		1,910,569
Issuance of common stock at $0.80 per share, net of direct offering costs of $59,931 (in shares)	2,463,125
BALANCES at Mar. 31, 2014	23,545,080	-18,957,371	4,587,709
BALANCES (in shares) at Mar. 31, 2014	10,673,225		10,673,225
Increase (Decrease) in Stockholders' Equity
Net loss		-1,382,746	-1,382,746
Compensation expense related to stock options	62,608		62,608
BALANCES at Mar. 31, 2015	$23,607,688	($20,340,117)	$3,267,571
BALANCES (in shares) at Mar. 31, 2015	10,673,225		10,673,225

Statements_of_Shareholders_Equ1

Statements of Shareholders' Equity (Parenthetical) (USD $)	12 Months Ended
	Mar. 31, 2014
Statements of Shareholders' Equity
Common stock, issue value (in dollars per share)	$0.80
Issuance of common stock, direct offering costs	$59,931

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	($1,382,746)	($1,781,678)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	382,058	499,066
Impairment of furniture, fixtures and equipment		643,867
Provision for impairment		456,501
Stock-based compensation expense related to stock options	62,608	64,518
Provision for doubtful accounts, net change after impairment of inventory	3,500	-1,000
Provision for inventory obsolescence, net change	136,501	52,499
Change in operating assets and liabilities:
Accounts receivable	-105,635	123,550
Inventories	-249,927	196,074
Prepaid expenses and other assets	-50,299	-4,408
Accounts payable	9,252	-157,188
Accrued compensation and other accrued liabilities	-238,083	19,405
Net cash (used in) operating activities	-1,432,771	111,206
Cash flows from investing activities:
Acquisition of property and equipment	-29,695	-421,855
Patent costs	-32,458	-36,564
Net cash (used in) investing activities	-62,153	-458,419
Cash flows from financing activities:
Borrowings from credit facility	64,000
Proceeds from the issuance of common stock		1,970,500
Cost of the issuance of common stock		-59,931
Net cash provided by financing activities	64,000	1,910,569
Net decrease in cash and cash equivalents	-1,430,924	1,563,356
Cash and cash equivalents, beginning of period	1,689,580	126,224
Cash and cash equivalents, end of period	258,656	1,689,580
Supplemental disclosures of cash flow information:
Cash paid during the year for interest	1,250	22,888
Furniture, fixtures and equipment acquired through leasehold improvements		$172,176

Description_of_Business

Description of Business	12 Months Ended
	Mar. 31, 2015
Description of Business
Description of Business
	1. Description of Business
	Encision Inc. is a medical device company that designs, develops, manufactures and markets patented surgical instruments that provide greater safety to patients undergoing minimally-invasive surgery. We believe that our patented AEM® surgical instrument technology is changing the marketplace for electrosurgical devices and instruments by providing a solution to a well-documented risk in laparoscopic surgery. Our sales to date have been made primarily in the United States.
	We have an accumulated deficit of $20,340,117 at March 31, 2015. Operating funds have been provided primarily by issuances of our common stock and warrants, the exercise of stock options to purchase our common stock, and, in recent years, by operating profits. Our liquidity has diminished because of prior years’ operating losses, and we may be required to seek additional capital in the future.
	Our strategic marketing and sales plan is designed to expand the use of our products in surgically active hospitals in the United States.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2015
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies
	2. Summary of Significant Accounting Policies
	Use of Estimates in the Preparation of Financial Statements.  The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions. Such estimates and assumptions affect the reported amounts of assets and liabilities as well as disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of sales and expense during the reporting period. Actual results could differ from those estimates.
	Cash and Cash Equivalents.  For purposes of reporting cash flows, we consider all cash and highly liquid investments with an original maturity of three months or less to be cash equivalents.
	Fair Value of Financial Instruments.  Our financial instruments consist of cash and cash equivalents and short-term trade receivables, payables and line of credit. The carrying values of cash and cash equivalents, short-term receivables, payables and line of credit approximate their fair value due to their short maturities.
	Concentration of Credit Risk. Financial instruments, which potentially subject us to concentrations of credit risk, consist of cash and cash equivalents, accounts receivable and accounts payable. The carrying value of all financial instruments approximates fair value. The amount of cash on deposit with financial institutions occasionally exceeds the $250,000 federally insured limit at March 31, 2015. However, we believe that cash on deposit that exceeds $250,000 in the financial institutions is financially sound and the risk of loss is minimal.
	We have no significant off-balance sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. We maintain the majority of our cash balances with one financial institution in the form of demand deposits.
	Accounts receivable are typically unsecured and are derived from transactions with and from entities in the healthcare industry primarily located in the United States. Accordingly, we may be exposed to credit risk generally associated with the healthcare industry. We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. We charge interest on past due accounts on a case-by-case basis.
	A summary of the activity in our allowance for doubtful accounts is as follows:
	Years Ended	March 31, 2015			March 31, 2014
	Balance, beginning of year	$	8,000		$	9,000
	Provision for estimated losses	9,582			4,042
	Write-off of uncollectible accounts	(6,082		)	(5,042		)
	Balance, end of year	$	11,500		$	8,000
	The net accounts receivable balance at March 31, 2015 of $965,355 included no more than 5% from any one customer. The net accounts receivable balance at March 31, 2014 of $863,220 included no more than 5% from any one customer.
	Warranty Accrual.  We provide for the estimated cost of product warranties at the time sales are recognized. While we engage in extensive product quality programs and processes, including actively monitoring and evaluating the quality of our component suppliers, our warranty obligation is based upon historical experience and is also affected by product failure rates and material usage incurred in correcting a product failure. Should actual product failure rates or material usage costs differ from our estimates, revisions to the estimated warranty liability would be required. A summary of our warranty claims activity, included in other accrued liabilities, is as follows:
	Years Ended	March 31, 2015			March 31, 2014
	Balance, beginning of year	$	35,000		$	55,000
	Provision for estimated warranty claims	(15,000		)	(20,000		)
	Claims made	—			—
	Balance, end of year	$	20,000		$	35,000
	Inventories. Inventories are stated at the lower of cost (first-in, first-out basis) or market. We reduce inventory for estimated obsolete or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. At March 31, 2015 and 2014, inventory consisted of the following:
		March 31, 2015			March 31, 2014
	Raw materials	$	1,547,733		$	1,498,867
	Finished goods	1,029,921			1,285,361
	Total gross inventories	2,577,654			2,784,228
	Less reserve for obsolescence	(240,000		)	(560,000		)
	Total net inventories	$	2,337,654		$	2,224,228
	A summary of the activity in our inventory reserve for obsolescence is as follows:
	Years Ended	March 31, 2015			March 31, 2014
	Balance, beginning of year	$	560,000		$	51,000
	Provision for estimated obsolescence	135,902			106,528
	Provision for impairment	—			456,501
	Write-off of obsolete inventory	(455,902		)	(54,029		)
	Balance, end of year	$	240,000		$	560,000
	Property and Equipment.  Property and equipment are stated at cost, with depreciation computed over the estimated useful lives of the assets, generally three to seven years. We use the straight-line method of depreciation for property and equipment. Leasehold improvements are depreciated over the shorter of the remaining lease term or the estimated useful life of the asset. Maintenance and repairs are expensed as incurred and major additions, replacements and improvements are capitalized. Equipment-in-progress is primarily manufacturing equipment for product that will be produced internally. Depreciation expense for the years ended March 31, 2015 and 2014 was $357,985 and $473,867, respectively.
	Long-Lived Assets.  Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. A long-lived asset is considered impaired when estimated future cash flows related to the asset, undiscounted and without interest, are insufficient to recover the carrying amount of the asset. If deemed impaired, the long-lived asset is reduced to its estimated fair value. Long-lived assets to be disposed of are reported at the lower of their carrying amount or estimated fair value less cost to sell. See Note 10.
	Patents.  The costs of applying for patents are capitalized and amortized on a straight-line basis over the lesser of the patent’s economic or legal life (20 years from the date of application in the United States). Capitalized costs are expensed if patents are not issued. We review the carrying value of our patents periodically to determine whether the patents have continuing value and such reviews could result in the conclusion that the recorded amounts have been impaired. A summary of our patents at March 31, 2015 and 2014 is as follows:
		March 31, 2015			March 31, 2014
	Patents issued	$	280,669		$	367,217
	Accumulated amortization	(153,494		)	(215,969		)
	Patents issued, net of accumulated amortization	127,175			151,248
	Patent applications	130,181			97,723
	Total net patents and patent applications	$	257,356		$	248,971
	The expected annual amortization expense related to patents and patent applications as of March 31, 2015, for the next five fiscal years, is as follows:
	Fiscal Year	Amount
	2016	$	21,924
	2017	21,924
	2018	21,924
	2019	21,924
	2020 and following	169,660
	Total	$	257,356
	Other Accrued Liabilities. At March 31, 2015 and 2014, other accrued liabilities consisted of the following:
		March 31, 2015			March 31, 2014
	Warranty	$	20,000		$	35,000
	Sales commissions	82,132			38,065
	Lease normalization	22,655			6,310
	Sales and use tax	21,124			18,108
	Marketing fees	8,133			10,560
	Legal and audit fees	38,493			45,439
	Payroll taxes	24,120			23,554
	Medical device tax	7,651			8,425
	Employment agreement	87,282			120,000
	Trade shows	—			50,000
Miscellaneous	13,336			53,088
Total other accrued liabilities	$	324,926		$	408,549
Income Taxes.  We account for income taxes under the provisions of ASC Topic 740, “Accounting for Income Taxes” (“ASC 740”). ASC 740 requires recognition of deferred income tax assets and liabilities for the expected future income tax consequences, based on enacted tax laws, of temporary differences between the financial reporting and tax bases of assets and liabilities. ASC 740 also requires recognition of deferred tax assets for the expected future tax effects of all deductible temporary differences, loss carryforwards and tax credit carryforwards. Deferred tax assets are then reduced, if deemed necessary, by a valuation allowance for the amount of any tax benefits which, more likely than not based on current circumstances, are not expected to be realized. Should we achieve sufficient, sustained income in the future, we may conclude that some or all of the valuation allowance should be reversed (Note 5).
ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts.
The cumulative effect of adopting ASC 740 on April 1, 2007 has been recorded net in deferred tax assets, which resulted in no ASC 740 liability on the balance sheet. The total amount of unrecognized tax benefits as of the date of adoption was zero. There are open statutes of limitations for taxing authorities in federal and state jurisdictions to audit the Company’s tax returns from fiscal year ended March 31, 1999 through the current period. Our policy is to account for income tax related interest and penalties in income tax expense in the statement of operations. There have been no income tax related interest or penalties assessed or recorded. Because the Company has provided a full valuation allowance on all of its deferred tax assets, the adoption of ASC 740 had no impact on our effective tax rate.
Sales Recognition.  Sales from product sales are recorded when we ship the product and title has passed to the customer, provided that we have evidence of a customer arrangement and can conclude that collection is probable. Our shipping policy is FOB Shipping Point. We recognize revenue from sales to stocking distributors when there is no right of return, other than for normal warranty claims. We have no ongoing obligations related to product sales, except for normal warranty. Revenue from engineering services is recognized when invoices are sent to customers and the service is performed.
Sales Taxes.  We collect sales tax from customers and remit the entire amount to each respective state. We recognize revenue from product sales net of sale taxes.
Research and Development Expenses.  We expense research and development costs for products and processes as incurred.
Advertising Costs.  We expense advertising costs as incurred. Advertising expense for the years ended March 31, 2015 and 2014 was minimal.
Medical Device Tax.  In March 2010, the Patient Protection and Affordable Care Act was enacted in the United States. This legislation includes a provision that imposes a 2.3% excise tax on the sale of certain medical devices by a manufacturer, producer or importer of such devices in the United States starting after December 31, 2012. We expense the medical device tax in Other Expense.
Stock-Based Compensation. Stock-based compensation is presented in accordance with the guidance of ASC Topic 718, “Compensation — Stock Compensation” (“ASC 718”). Under the provisions of ASC 718, companies are required to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our statement of operations.
ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the accompanying statement of operations.
Stock-based compensation expense recognized during the period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Stock-based compensation expense recognized in our statement of operations for fiscal years 2015 and 2014 included compensation expense for share-based payment awards granted prior to, but not yet vested as of March 31, 2015, based on the grant date fair value. Compensation expense for all share-based payment is recognized using the straight-line, single-option method. As stock-based compensation expense recognized in the accompanying statement of operations for fiscal years 2015 and 2014 is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
We used the Black-Scholes option-pricing model (“Black-Scholes model”) to determine fair value. Our determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to our expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Although the fair value of employee stock options is determined in accordance with ASC 718 using an option-pricing model, that value may not be indicative of the fair value observed in a willing buyer/willing seller market transaction.
Stock-based compensation expense recognized under ASC 718 for fiscal years 2015 and 2014 was $62,608 and $64,518, respectively, which consisted of stock-based compensation expense related to director and employee stock options.
Stock-based compensation expense related to employee stock options under ASC 718 for fiscal years 2015 and 2014 was allocated as follows:
Years Ended	March 31, 2015			March 31, 2014
Cost of sales	$	1,965		$	1,381
Sales and marketing	11,076			10,420
General and administrative	46,522			44,854
Research and development	3,045			7,863
Stock-based compensation expense	$	62,608		64,518
Segment Reporting.  We have concluded that we have one operating segment.
Basic and Diluted Income per Common Share.  Net income per share is calculated in accordance with ASC Topic 260, “Earnings Per Share” (“ASC 260”). Under the provisions of ASC 260, basic net income per common share is computed by dividing net income for the period by the weighted average number of common shares outstanding for the period. Diluted net income per common share is computed by dividing the net income for the period by the weighted average number of common and potential common shares outstanding during the period if the effect of the potential common shares is dilutive. Because we had a loss in fiscal years 2015 and 2014, the shares used in the calculation of dilutive potential common shares exclude options to purchase shares and RSUs. Therefore, basic net loss per common share equals dilutive net loss per common share:
The following table presents the calculation of basic and diluted net income (loss) per share:
Years Ended	March 31, 2015			March 31, 2014
Net loss	$	(1,382,746	)	$	(1,781,678	)
Weighted-average shares — basic	10,673,225			8,921,669
Effect of dilutive potential common shares	—			—
Weighted-average shares — diluted	10,673,225			8,921,669
Net loss per share — basic and diluted	$	(0.13	)	$	(0.20	)
Antidilutive equity units	599,924			531,000
Recent Accounting Pronouncements.  We have reviewed all recently issued, but not yet effective, accounting pronouncements. The Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09 (Revenue from Contracts with Customers), which is effective for annual reporting periods beginning after December 15, 2016. We have not yet assessed the impact, if any, of adopting this standard. The Financial Accounting Standards Board has also issued Accounting Standards Update 2014-15, Presentation of Financial Statements — Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (the ASU), which provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. The ASU requires management to perform an assessment every reporting period (including interim periods) to determine whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. The ASU also defines that substantial doubt exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). The ASU applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. We are currently evaluating this new guidance and the related impact on the financial statements.

Shareholders_Equity

Shareholders' Equity	12 Months Ended
	Mar. 31, 2015
Shareholders' Equity
Shareholders' Equity
	3. Shareholders’ Equity
	Stock Option Plans.  We have a stock option plan, the 2007 Stock Option Plan, and we adopted our 2014 Equity Incentive Plan (the “Plan,” as summarized below) to promote our and our shareholders’ interests by helping us to attract, retain and motivate our key employees and associates. Under the terms of the Plan, the Board of Directors may grant incentive and non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance units, and other stock-based awards. The purchase price of the shares subject to a stock option will be the fair market value of our common stock on the date the stock option is granted. Generally, vesting of stock options occurs such that 20% becomes exercisable on each anniversary of the date of grant for each of the five years following the grant date of such option. Generally, all stock options must be exercised within five years from the date granted. The number of common shares reserved for issuance under the Plan is 700,000 shares of common stock, subject to adjustment for dividend, stock split or other relevant changes in our capitalization.
	Under ASC 718, the value of each employee stock option was estimated on the date of grant using the Black-Scholes model for the purpose of financial information in accordance with ASC 718. The use of a Black-Scholes model requires the use of actual employee exercise behavior data and the use of a number of assumptions including expected volatility, risk-free interest rate and expected dividends. Employee stock options for 95,000 and 405,000 shares of stock were granted during fiscal years 2015 and 2014, respectively. RSUs for 24,924 and no shares of stock were granted during fiscal years 2015 and 2014, respectively.
	As of March 31, 2015, $266,000 of total unrecognized compensation costs related to nonvested stock is expected to be recognized over a period of five years. The assumptions for employee stock options are summarized as follows:
	Years Ended	March 31, 2015		March 31, 2014
	Risk-free interest rate	1.4% to 1.7%		0.7% to 1.7%
	Expected life (in years)	5		5
	Expected volatility	74% to 75%		75% to 106%
	Expected dividend	0%		0%
	Cumulative compensation cost recognized in net income or loss with respect to options that are forfeited prior to vesting is adjusted as a reduction of compensation expense in the period of forfeiture. The volatility of the stock is based on the historical volatility for the period that approximates the expected lives of the options being valued. Fair value computations are highly sensitive to the volatility factor; the greater the volatility, the higher the computed fair value of options granted.
	The total fair value of options granted was computed to be approximately $51,000 and $275,000, for the fiscal years ended March 31, 2015 and 2014, respectively. For disclosure purposes, these amounts are amortized ratably over the vesting periods of the options. Effects of stock-based compensation, net of the effect of forfeitures, totaled $62,608 and $64,518 for fiscal years 2015 and 2014, respectively.
	The Black-Scholes model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. In addition, option valuation models require the use of assumptions, including the expected stock price volatility. Because our employee stock options have characteristics significantly different than those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of our employee stock options. A summary of our stock option activity and related information for equity compensation plans approved by security holders for each of the fiscal years ended March 31, 2015 and 2014 is as follows:
		STOCK OPTIONS OUTSTANDING
		Number		Weighted-Average
		Outstanding		Exercise Price per
				Share
	BALANCE AT MARCH 31, 2013	437,000		$	1.24
	Granted	185,000		0.99
	Forfeited/expired	(341,000	)	1.25
	BALANCE AT MARCH 31, 2014	281,000		$	1.06
	Granted	75,000		0.84
	Forfeited/expired	(26,000	)	1.73
	BALANCE AT MARCH 31, 2015	330,000		$	0.96
	A summary of our stock option activity and related information for equity compensation plans not approved by security holders for the fiscal year ended March 31, 2015 is as follows:
		STOCK OPTIONS OUTSTANDING
		Number		Weighted-Average
		Outstanding		Exercise Price per
				Share
	BALANCE AT MARCH 31, 2013	110,000		$	1.15
	Granted	220,000		0.93
	Forfeited/expired	(80,000	)	1.1
	BALANCE AT MARCH 31, 2014	250,000		$	0.97
	Granted	20,000		1
	Forfeited/expired	(25,000	)	1.12
	BALANCE AT MARCH 31, 2015	245,000		$	0.96
	The following table summarizes information about employee stock options outstanding and exercisable at March 31, 2015:
		STOCK OPTIONS OUTSTANDING						STOCK OPTIONS EXERCISABLE
	Range of Exercise Prices	Number		Weighted-Average		Weighted-Average		Number	Weighted-Average
		Outstanding		Remaining Contractual		Exercise Price		Exercisable	Exercise Price
				Life (in Years)		per Share			per Share
	$ 0.60 - $0.94	345,000		3.5		$	0.83	69,296	$	0.79
	$ 1.00 - $1.09	110,000		3.4		$	1.02	35,856	$	1.04
	$ 1.10 - $1.50	120,000		3.1		$	1.26	58,180	$	1.28
		575,000		3.4		$	0.96	163,332	$	1.02
	A summary of our RSU activity and related information for equity compensation plans approved by security holders for the fiscal year ended March 31, 2015 is as follows:
		RSUs OUTSTANDING
		Number		Weighted-Average
		Outstanding		Exercise Price per
				Share
	BALANCE AT MARCH 31, 2014	—		$	—
	Granted	24,924		0.80
	BALANCE AT MARCH 31, 2015	24,924		$	0.80
	The 575,000 options outstanding as of March 31, 2015 are nonqualified stock options. The exercise price of all options granted through March 31, 2015 has been equal to or greater than the fair market value, as determined by our Board of Directors or based upon publicly quoted market values of our common stock on the date of the grant. As of March 31, 2015, 600,076 equity units for our common stock remain available for grant under the Plan.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Mar. 31, 2015
Commitments and Contingencies
Commitments and Contingencies
	4. Commitments and Contingencies
	Effective December 1, 2013, we extended our noncancelable lease agreement through July 31, 2019 for 28,696 square feet of space for our facilities at 6797 Winchester Circle, Boulder, Colorado. The lease includes $172,176 of leasehold improvements granted by the landlord. The $172,176 was recorded on our balance sheets as leasehold improvements and deferred rent. The leasehold improvements are being amortized over the lesser of the lease term or the assets life and the deferred rent is being amortized against rent expense over the lease term. The minimum future lease payment, by fiscal year, as of March 31, 2015 is as follows:
	Fiscal Year	Amount
	2016	268,672
	2017	276,732
	2018	285,034
	2019	293,585
	2020	99,800
	Total	$	1,223,823
	We paid off our capital equipment lease with General Electric Capital Corporation and, at March 31, 2015, have no balance remaining.
	Included in our furniture, fixtures and equipment balance is leased equipment that was acquired, under the provisions of a long-term capital lease, during the quarter ended June 30, 2013. The equipment had an original cost of $177,547 and has a net book value of $86,069 at March 31, 2015.
	On May 29, 2015, we signed an amendment to our credit facility agreement with Silicon Valley Bank. The terms of the credit facility include a line of credit for $2,000,000 for one year, until May 29, 2016, at an interest rate calculated at the prime rate plus 1.25%, subject to increase upon a default. The liquidity ratio covenant limits our borrowing under the credit facility by a ratio of at least 2.0 to 1.0 of our eligible receivables plus cash, minus accounts payable that are over sixty days, at the time of borrowing. As of March 31, 2015, we had $64,000 of borrowings from the credit facility and, under our liquidity ratio limit, had an additional approximately $517,000 available to borrow. The credit facility is secured by all tangible and intangible assets, whether now owned or hereafter acquired, wherever located. Our credit facility is classified in the balance sheets as a long-term liability.
	We are subject to regulation by the United States Food and Drug Administration (“FDA”). The FDA provides regulations governing the manufacture and sale of our products and regularly inspects us and other manufacturers to determine our and their compliance with these regulations. As of March 31, 2015, we believe we were in substantial compliance with all known regulations. FDA inspections are conducted periodically at the discretion of the FDA. We were last inspected in December 2012 and were notified of five observations from that inspection, none of which we believe to be material.
	Our obligation with respect to employee severance benefits is minimized by the “at will” nature of the employee relationships. Our total obligation as of March 31, 2015 with respect to contingent severance benefit obligations was $87,282.

Income_Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2015
Income Taxes
Income Taxes
	5. Income Taxes
	We account for income taxes under ASC 740, which requires the use of the liability method. ASC 740 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. Deferred tax assets and liabilities at the end of each period are determined using the currently enacted tax rates applied to taxable income in the periods in which the deferred tax assets and liabilities are expected to be settled or realized.
	Income tax provision (benefit) for income taxes is summarized below:
	Years Ended	March 31, 2015			March 31, 2014
	Current:
	Federal	$	—		$	—
	State	—			—
	Total current	—			—
	Deferred:
	Federal	(461,000		)	(583,000		)
	State	(48,000		)	(60,000		)
	Total deferred	(509,000		)	(643,000		)
	Valuation allowance	509,000			643,000
	Total	$	—		$	—
	The items accounting for the difference between income taxes computed at the federal statutory rate and the provision for income taxes consists of the following:
	Years Ended	March 31, 2015			March 31, 2014
	Federal statutory rate	$	(470,000	)	$	(606,000	)
	Effect of:
	State taxes, net of federal tax benefit	(48,000		)	(62,000		)
	Other	12,000			22,000
	Valuation allowance	506,000			646,000
	Total	$	—		$	—
	The components of the deferred tax asset are as follows:
	Years Ended	March 31, 2015			March 31, 2014
	Credits and net operating loss carryforwards	$	3,936,000		$	3,067,000
	Impairment reserve	—			412,000
	Other	158,000			106,000
	Gross deferred tax assets	4,094,000			3,585,000
	Valuation allowance	(4,094,000		)	(3,585,000		)
	Total deferred tax assets	$	—		$	—
	We believe that based on all available evidence, it is more likely than not that the deferred tax assets will not be fully realized. Accordingly, a valuation allowance has been recorded against the deferred tax asset.
	As of March 31, 2015, we had approximately $10.5 million of net operating loss carryovers for tax purposes. Additionally, we have approximately $214,000 of research and development tax credits available to offset future federal income taxes. The net operating loss and credit carryovers begin to expire in the fiscal year ended March 31, 2019. In fiscal years ended after March 31, 2019, net operating losses expire at various dates through March 31, 2035. Our net operating loss carryovers at March 31, 2015 include $582,000 in income tax deductions related to stock options which will be tax effected and the benefit will be reflected as a credit to additional paid-in capital when realized. As such, these deductions are not reflected in our deferred tax assets. The Internal Revenue Code contains provisions, which may limit the net operating loss carryforwards available to be used in any given year if certain events occur, including significant changes in ownership interests.

Legal_Proceedings

Legal Proceedings	12 Months Ended
	Mar. 31, 2015
Legal Proceedings
Legal Proceedings
	6. Legal Proceedings
	We have been named as a defendant in 59 separate (but similar) product liability lawsuits relating to a surgical mesh product manufactured by another company. We did not distribute or sell the manufacturer’s mesh product, which is the subject of these lawsuits. We believe that we have been named as a defendant in these lawsuits only because we served as a distributor for other unrelated products of that manufacturer. We believe that we have meritorious defenses to these lawsuits. We believe that these lawsuits will be covered by our insurance policies.
	Based on currently available information, we believe that the resolution of these lawsuits is not likely to have a material adverse effect on our business, financial position or future results of operations. In accordance with generally accepted accounting principles in the United States (U.S. GAAP), we record a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These provisions are reviewed at least quarterly and adjusted to reflect the impacts of negotiations, settlements, rulings, advice of legal counsel, and other information and events pertaining to a particular case.

Major_CustomersSuppliers

Major Customers/Suppliers	12 Months Ended
	Mar. 31, 2015
Major Customers/Suppliers
Major Customers/Suppliers
	7. Major Customers/Suppliers
	We depend on sales that are generated from hospitals’ ongoing usage of AEM surgical instruments. In fiscal year 2015, we generated sales from over 350 hospitals that have changed to AEM products, but no hospital customer contributed more than 3% to the total sales. We have a relationship with New Deantronics, Inc., who accounted for approximately 11% of our purchases in fiscal year 2015

Defined_Contribution_Employee_

Defined Contribution Employee Benefit Plan	12 Months Ended
	Mar. 31, 2015
Defined Contribution Employee Benefit Plan
Defined Contribution Employee Benefit Plan
	8. Defined Contribution Employee Benefit Plan
	We have adopted a 401(k) Profit Sharing Plan which covers all full-time employees who have completed at least three months of full-time continuous service and are age eighteen or older. Participants may defer up to 20% of their gross pay up to a maximum limit determined by law. Participants are immediately vested in their contributions. We may make discretionary contributions based on corporate financial results for the fiscal year. To date, we have not made contributions to the 401(k) Profit Sharing Plan. Vesting in a contribution account (our contribution) is based on years of service, with a participant fully vested after five years of credited service.

Related_Party_Transaction

Related Party Transaction	12 Months Ended
	Mar. 31, 2015
Related Party Transaction
Related Party Transaction
	9. Related Party Transaction
	We paid consulting fees of $84,733 and $92,308 to an entity owned by one of our directors in fiscal years 2015 and 2014, respectively. We paid consulting fees of $4,000 and $89,519 to an entity owned by another director, in fiscal years 2015 and 2014, respectively.

Impairment_Cost

Impairment Cost	12 Months Ended
	Mar. 31, 2015
Impairment Cost.
Impairment Cost
	10. Impairment Cost
	After assessing poor performance of our pistol-grip disposable suction irrigation electrode and our cold scissors, we decided to discontinue future sales of these instruments. As a result, we incurred a product impairment cost of $1,100,368 in our fourth quarter that ended March 31, 2014, for inventory and equipment of these instruments and for other inventory that we will not use in the future. Impairment of furniture, fixtures and equipment was $643,867 and impairment of inventory was $456,501.

Subsequent_Events

Subsequent Events	12 Months Ended
	Mar. 31, 2015
Subsequent Events
Subsequent Events
	11. Subsequent Events
	Management evaluated all activity of us and concluded that, except for the events that follows, no subsequent events have occurred that would require recognition in the financial statements or disclosure in the notes to the financial statements.
	On May 29, 2015, we signed an amendment to our credit facility agreement with Silicon Valley Bank. The terms of the credit facility include a line of credit for $2,000,000 for one year, until May 29, 2016, at an interest rate calculated at the prime rate plus 1.25%, subject to increase upon a default. The liquidity ratio covenant of the agreement limits our borrowing under the credit facility by a ratio of at least 2.0 to 1.0 of our eligible receivables plus cash, minus accounts payable that are over sixty days, at the time of borrowing. As of March 31, 2015, we had $64,000 of borrowings from the credit facility and, under our liquidity ratio limit, had an additional approximately $517,000 available to borrow. The credit facility is secured by all tangible and intangible assets, whether now owned or hereafter acquired, wherever located. Our credit facility is classified in the balance sheets as a long-term liability.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2015
Summary of Significant Accounting Policies
Use of Estimates in the Preparation of Financial Statements
	Use of Estimates in the Preparation of Financial Statements.  The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions. Such estimates and assumptions affect the reported amounts of assets and liabilities as well as disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of sales and expense during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents
	Cash and Cash Equivalents.  For purposes of reporting cash flows, we consider all cash and highly liquid investments with an original maturity of three months or less to be cash equivalents.
Fair Value of Financial Instruments
	Fair Value of Financial Instruments.  Our financial instruments consist of cash and cash equivalents and short-term trade receivables, payables and line of credit. The carrying values of cash and cash equivalents, short-term receivables, payables and line of credit approximate their fair value due to their short maturities.
Concentration of Credit Risk
	Concentration of Credit Risk. Financial instruments, which potentially subject us to concentrations of credit risk, consist of cash and cash equivalents, accounts receivable and accounts payable. The carrying value of all financial instruments approximates fair value. The amount of cash on deposit with financial institutions occasionally exceeds the $250,000 federally insured limit at March 31, 2015. However, we believe that cash on deposit that exceeds $250,000 in the financial institutions is financially sound and the risk of loss is minimal.
	We have no significant off-balance sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. We maintain the majority of our cash balances with one financial institution in the form of demand deposits.
	Accounts receivable are typically unsecured and are derived from transactions with and from entities in the healthcare industry primarily located in the United States. Accordingly, we may be exposed to credit risk generally associated with the healthcare industry. We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. We charge interest on past due accounts on a case-by-case basis.
	A summary of the activity in our allowance for doubtful accounts is as follows:
	Years Ended	March 31, 2015			March 31, 2014
	Balance, beginning of year	$	8,000		$	9,000
	Provision for estimated losses	9,582			4,042
	Write-off of uncollectible accounts	(6,082		)	(5,042		)
	Balance, end of year	$	11,500		$	8,000
	The net accounts receivable balance at March 31, 2015 of $965,355 included no more than 5% from any one customer. The net accounts receivable balance at March 31, 2014 of $863,220 included no more than 5% from any one customer.
Warranty Accrual
	Warranty Accrual.  We provide for the estimated cost of product warranties at the time sales are recognized. While we engage in extensive product quality programs and processes, including actively monitoring and evaluating the quality of our component suppliers, our warranty obligation is based upon historical experience and is also affected by product failure rates and material usage incurred in correcting a product failure. Should actual product failure rates or material usage costs differ from our estimates, revisions to the estimated warranty liability would be required. A summary of our warranty claims activity, included in other accrued liabilities, is as follows:
	Years Ended	March 31, 2015			March 31, 2014
	Balance, beginning of year	$	35,000		$	55,000
	Provision for estimated warranty claims	(15,000		)	(20,000		)
	Claims made	—			—
	Balance, end of year	$	20,000		$	35,000
Inventories
	Inventories. Inventories are stated at the lower of cost (first-in, first-out basis) or market. We reduce inventory for estimated obsolete or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. At March 31, 2015 and 2014, inventory consisted of the following:
		March 31, 2015			March 31, 2014
	Raw materials	$	1,547,733		$	1,498,867
	Finished goods	1,029,921			1,285,361
	Total gross inventories	2,577,654			2,784,228
	Less reserve for obsolescence	(240,000		)	(560,000		)
	Total net inventories	$	2,337,654		$	2,224,228
	A summary of the activity in our inventory reserve for obsolescence is as follows:
	Years Ended	March 31, 2015			March 31, 2014
	Balance, beginning of year	$	560,000		$	51,000
	Provision for estimated obsolescence	135,902			106,528
	Provision for impairment	—			456,501
	Write-off of obsolete inventory	(455,902		)	(54,029		)
	Balance, end of year	$	240,000		$	560,000
Property and Equipment
	Property and Equipment.  Property and equipment are stated at cost, with depreciation computed over the estimated useful lives of the assets, generally three to seven years. We use the straight-line method of depreciation for property and equipment. Leasehold improvements are depreciated over the shorter of the remaining lease term or the estimated useful life of the asset. Maintenance and repairs are expensed as incurred and major additions, replacements and improvements are capitalized. Equipment-in-progress is primarily manufacturing equipment for product that will be produced internally. Depreciation expense for the years ended March 31, 2015 and 2014 was $357,985 and $473,867, respectively.
Long-Lived Assets
	Long-Lived Assets.  Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. A long-lived asset is considered impaired when estimated future cash flows related to the asset, undiscounted and without interest, are insufficient to recover the carrying amount of the asset. If deemed impaired, the long-lived asset is reduced to its estimated fair value. Long-lived assets to be disposed of are reported at the lower of their carrying amount or estimated fair value less cost to sell. See Note 10.
Patents
	Patents.  The costs of applying for patents are capitalized and amortized on a straight-line basis over the lesser of the patent’s economic or legal life (20 years from the date of application in the United States). Capitalized costs are expensed if patents are not issued. We review the carrying value of our patents periodically to determine whether the patents have continuing value and such reviews could result in the conclusion that the recorded amounts have been impaired. A summary of our patents at March 31, 2015 and 2014 is as follows:
		March 31, 2015			March 31, 2014
	Patents issued	$	280,669		$	367,217
	Accumulated amortization	(153,494		)	(215,969		)
	Patents issued, net of accumulated amortization	127,175			151,248
	Patent applications	130,181			97,723
	Total net patents and patent applications	$	257,356		$	248,971
	The expected annual amortization expense related to patents and patent applications as of March 31, 2015, for the next five fiscal years, is as follows:
	Fiscal Year	Amount
	2016	$	21,924
	2017	21,924
	2018	21,924
	2019	21,924
	2020 and following	169,660
	Total	$	257,356
Other Accrued Liabilities
	Other Accrued Liabilities. At March 31, 2015 and 2014, other accrued liabilities consisted of the following:
		March 31, 2015			March 31, 2014
	Warranty	$	20,000		$	35,000
	Sales commissions	82,132			38,065
	Lease normalization	22,655			6,310
	Sales and use tax	21,124			18,108
	Marketing fees	8,133			10,560
	Legal and audit fees	38,493			45,439
	Payroll taxes	24,120			23,554
	Medical device tax	7,651			8,425
	Employment agreement	87,282			120,000
	Trade shows	—			50,000
	Miscellaneous	13,336			53,088
	Total other accrued liabilities	$	324,926		$	408,549
Income Taxes
	Income Taxes.  We account for income taxes under the provisions of ASC Topic 740, “Accounting for Income Taxes” (“ASC 740”). ASC 740 requires recognition of deferred income tax assets and liabilities for the expected future income tax consequences, based on enacted tax laws, of temporary differences between the financial reporting and tax bases of assets and liabilities. ASC 740 also requires recognition of deferred tax assets for the expected future tax effects of all deductible temporary differences, loss carryforwards and tax credit carryforwards. Deferred tax assets are then reduced, if deemed necessary, by a valuation allowance for the amount of any tax benefits which, more likely than not based on current circumstances, are not expected to be realized. Should we achieve sufficient, sustained income in the future, we may conclude that some or all of the valuation allowance should be reversed (Note 5).
	ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts.
	The cumulative effect of adopting ASC 740 on April 1, 2007 has been recorded net in deferred tax assets, which resulted in no ASC 740 liability on the balance sheet. The total amount of unrecognized tax benefits as of the date of adoption was zero. There are open statutes of limitations for taxing authorities in federal and state jurisdictions to audit the Company’s tax returns from fiscal year ended March 31, 1999 through the current period. Our policy is to account for income tax related interest and penalties in income tax expense in the statement of operations. There have been no income tax related interest or penalties assessed or recorded. Because the Company has provided a full valuation allowance on all of its deferred tax assets, the adoption of ASC 740 had no impact on our effective tax rate.
Sales Recognition
	Sales Recognition.  Sales from product sales are recorded when we ship the product and title has passed to the customer, provided that we have evidence of a customer arrangement and can conclude that collection is probable. Our shipping policy is FOB Shipping Point. We recognize revenue from sales to stocking distributors when there is no right of return, other than for normal warranty claims. We have no ongoing obligations related to product sales, except for normal warranty. Revenue from engineering services is recognized when invoices are sent to customers and the service is performed.
Sales Taxes
	Sales Taxes.  We collect sales tax from customers and remit the entire amount to each respective state. We recognize revenue from product sales net of sale taxes.
Research and Development Expenses
	Research and Development Expenses.  We expense research and development costs for products and processes as incurred.
Advertising Costs
	Advertising Costs.  We expense advertising costs as incurred. Advertising expense for the years ended March 31, 2015 and 2014 was minimal.
Medical Device Tax
	Medical Device Tax.  In March 2010, the Patient Protection and Affordable Care Act was enacted in the United States. This legislation includes a provision that imposes a 2.3% excise tax on the sale of certain medical devices by a manufacturer, producer or importer of such devices in the United States starting after December 31, 2012. We expense the medical device tax in Other Expense.
Stock-Based Compensation
	Stock-Based Compensation. Stock-based compensation is presented in accordance with the guidance of ASC Topic 718, “Compensation — Stock Compensation” (“ASC 718”). Under the provisions of ASC 718, companies are required to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our statement of operations.
	ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the accompanying statement of operations.
	Stock-based compensation expense recognized during the period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Stock-based compensation expense recognized in our statement of operations for fiscal years 2015 and 2014 included compensation expense for share-based payment awards granted prior to, but not yet vested as of March 31, 2015, based on the grant date fair value. Compensation expense for all share-based payment is recognized using the straight-line, single-option method. As stock-based compensation expense recognized in the accompanying statement of operations for fiscal years 2015 and 2014 is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
	We used the Black-Scholes option-pricing model (“Black-Scholes model”) to determine fair value. Our determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to our expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Although the fair value of employee stock options is determined in accordance with ASC 718 using an option-pricing model, that value may not be indicative of the fair value observed in a willing buyer/willing seller market transaction.
	Stock-based compensation expense recognized under ASC 718 for fiscal years 2015 and 2014 was $62,608 and $64,518, respectively, which consisted of stock-based compensation expense related to director and employee stock options.
	Stock-based compensation expense related to employee stock options under ASC 718 for fiscal years 2015 and 2014 was allocated as follows:
	Years Ended	March 31, 2015			March 31, 2014
	Cost of sales	$	1,965		$	1,381
	Sales and marketing	11,076			10,420
	General and administrative	46,522			44,854
	Research and development	3,045			7,863
	Stock-based compensation expense	$	62,608		64,518
Segment Reporting
	Segment Reporting.  We have concluded that we have one operating segment.
Basic and Diluted Income per Common Share
	Basic and Diluted Income per Common Share.  Net income per share is calculated in accordance with ASC Topic 260, “Earnings Per Share” (“ASC 260”). Under the provisions of ASC 260, basic net income per common share is computed by dividing net income for the period by the weighted average number of common shares outstanding for the period. Diluted net income per common share is computed by dividing the net income for the period by the weighted average number of common and potential common shares outstanding during the period if the effect of the potential common shares is dilutive. Because we had a loss in fiscal years 2015 and 2014, the shares used in the calculation of dilutive potential common shares exclude options to purchase shares and RSUs. Therefore, basic net loss per common share equals dilutive net loss per common share:
	The following table presents the calculation of basic and diluted net income (loss) per share:
	Years Ended	March 31, 2015			March 31, 2014
	Net loss	$	(1,382,746	)	$	(1,781,678	)
	Weighted-average shares — basic	10,673,225			8,921,669
	Effect of dilutive potential common shares	—			—
	Weighted-average shares — diluted	10,673,225			8,921,669
	Net loss per share — basic and diluted	$	(0.13	)	$	(0.20	)
	Antidilutive equity units	599,924			531,000
Recent Accounting Pronouncements
	Recent Accounting Pronouncements.  We have reviewed all recently issued, but not yet effective, accounting pronouncements. The Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09 (Revenue from Contracts with Customers), which is effective for annual reporting periods beginning after December 15, 2016. We have not yet assessed the impact, if any, of adopting this standard. The Financial Accounting Standards Board has also issued Accounting Standards Update 2014-15, Presentation of Financial Statements — Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (the ASU), which provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. The ASU requires management to perform an assessment every reporting period (including interim periods) to determine whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. The ASU also defines that substantial doubt exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). The ASU applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. We are currently evaluating this new guidance and the related impact on the financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2015
Summary of Significant Accounting Policies
Summary of the activity in allowance for doubtful accounts	Years Ended	March 31, 2015			March 31, 2014
	Balance, beginning of year	$	8,000		$	9,000
	Provision for estimated losses	9,582			4,042
	Write-off of uncollectible accounts	(6,082		)	(5,042		)
	Balance, end of year	$	11,500		$	8,000
Summary of warranty claims activity, included in other accrued liabilities	Years Ended	March 31, 2015			March 31, 2014
	Balance, beginning of year	$	35,000		$	55,000
	Provision for estimated warranty claims	(15,000		)	(20,000		)
	Claims made	—			—
	Balance, end of year	$	20,000		$	35,000
Schedule of inventory			March 31, 2015			March 31, 2014
	Raw materials		$	1,547,733		$	1,498,867
	Finished goods		1,029,921			1,285,361
	Total gross inventories		2,577,654			2,784,228
	Less reserve for obsolescence		(240,000		)	(560,000		)
	Total net inventories		$	2,337,654		$	2,224,228
Summary of the activity in inventory reserve for obsolescence	Years Ended	March 31, 2015			March 31, 2014
	Balance, beginning of year	$	560,000		$	51,000
	Provision for estimated obsolescence	135,902			106,528
	Provision for impairment	—			456,501
	Write-off of obsolete inventory	(455,902		)	(54,029		)
	Balance, end of year	$	240,000		$	560,000
Summary of patents		March 31, 2015			March 31, 2014
	Patents issued	$	280,669		$	367,217
	Accumulated amortization	(153,494		)	(215,969		)
	Patents issued, net of accumulated amortization	127,175			151,248
	Patent applications	130,181			97,723
	Total net patents and patent applications	$	257,356		$	248,971
Schedule of expected annual amortization expense related to patents and patent applications for the next five fiscal years	Fiscal Year	Amount
	2016	$	21,924
	2017	21,924
	2018	21,924
	2019	21,924
	2020 and following	169,660
	Total	$	257,356
Schedule of other accrued liabilities		March 31, 2015			March 31, 2014
	Warranty	$	20,000		$	35,000
	Sales commissions	82,132			38,065
	Lease normalization	22,655			6,310
	Sales and use tax	21,124			18,108
	Marketing fees	8,133			10,560
	Legal and audit fees	38,493			45,439
	Payroll taxes	24,120			23,554
	Medical device tax	7,651			8,425
	Employment agreement	87,282			120,000
	Trade shows	—			50,000
	Miscellaneous	13,336			53,088
	Total other accrued liabilities	$	324,926		$	408,549
Schedule of stock-based compensation expense related to employee stock options	Years Ended	March 31, 2015			March 31, 2014
	Cost of sales	$	1,965		$	1,381
	Sales and marketing	11,076			10,420
	General and administrative	46,522			44,854
	Research and development	3,045			7,863
	Stock-based compensation expense	$	62,608		64,518
Schedule of calculation of basic and diluted net income (loss) per share	Years Ended	March 31, 2015			March 31, 2014
	Net loss	$	(1,382,746	)	$	(1,781,678	)
	Weighted-average shares — basic	10,673,225			8,921,669
	Effect of dilutive potential common shares	—			—
	Weighted-average shares — diluted	10,673,225			8,921,669
	Net loss per share — basic and diluted	$	(0.13	)	$	(0.20	)
	Antidilutive equity units	599,924			531,000

Shareholders_Equity_Tables

Shareholders' Equity (Tables)	12 Months Ended
	Mar. 31, 2015
Shareholders' Equity
Summary of assumptions for employee stock options	Years Ended	March 31, 2015		March 31, 2014
	Risk-free interest rate	1.4% to 1.7%		0.7% to 1.7%
	Expected life (in years)	5		5
	Expected volatility	74% to 75%		75% to 106%
	Expected dividend	0%		0%
Shareholders' Equity
Summary of information about employee stock options outstanding and exercisable
		STOCK OPTIONS OUTSTANDING						STOCK OPTIONS EXERCISABLE
	Range of Exercise Prices	Number		Weighted-Average		Weighted-Average		Number	Weighted-Average
		Outstanding		Remaining Contractual		Exercise Price		Exercisable	Exercise Price
				Life (in Years)		per Share			per Share
	$ 0.60 - $0.94	345,000		3.5		$	0.83	69,296	$	0.79
	$ 1.00 - $1.09	110,000		3.4		$	1.02	35,856	$	1.04
	$ 1.10 - $1.50	120,000		3.1		$	1.26	58,180	$	1.28
		575,000		3.4		$	0.96	163,332	$	1.02
Summary of RSU activity and related information for equity compensation plans		RSUs OUTSTANDING
		Number		Weighted-Average
		Outstanding		Exercise Price per
				Share
	BALANCE AT MARCH 31, 2014	—		$	—
	Granted	24,924		0.80
	BALANCE AT MARCH 31, 2015	24,924		$	0.80
Equity compensation plans approved by security holders
Shareholders' Equity
Summary of stock option activity and related information for equity compensation plans
		STOCK OPTIONS OUTSTANDING
		Number		Weighted-Average
		Outstanding		Exercise Price per
				Share
	BALANCE AT MARCH 31, 2013	437,000		$	1.24
	Granted	185,000		0.99
	Forfeited/expired	(341,000	)	1.25
	BALANCE AT MARCH 31, 2014	281,000		$	1.06
	Granted	75,000		0.84
	Forfeited/expired	(26,000	)	1.73
	BALANCE AT MARCH 31, 2015	330,000		$	0.96
Equity compensation plans not approved by security holders
Shareholders' Equity
Summary of stock option activity and related information for equity compensation plans
		STOCK OPTIONS OUTSTANDING
		Number		Weighted-Average
		Outstanding		Exercise Price per
				Share
	BALANCE AT MARCH 31, 2013	110,000		$	1.15
	Granted	220,000		0.93
	Forfeited/expired	(80,000	)	1.1
	BALANCE AT MARCH 31, 2014	250,000		$	0.97
	Granted	20,000		1
	Forfeited/expired	(25,000	)	1.12
	BALANCE AT MARCH 31, 2015	245,000		$	0.96

Commitments_and_Contingencies_

Commitments and Contingencies (Tables) (Facilities at 6797 Winchester Circle, Boulder, Colorado)	12 Months Ended
	Mar. 31, 2015
Facilities at 6797 Winchester Circle, Boulder, Colorado
Commitments and contingencies
Schedule of minimum future lease payments, by fiscal year	Fiscal Year	Amount
	2016	268,672
	2017	276,732
	2018	285,034
	2019	293,585
	2020	99,800
	Total	$	1,223,823

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2015
Income Taxes
Schedule of income tax provision (benefit) for income taxes	Years Ended	March 31, 2015			March 31, 2014
	Current:
	Federal	$	—		$	—
	State	—			—
	Total current	—			—
	Deferred:
	Federal	(461,000		)	(583,000		)
	State	(48,000		)	(60,000		)
	Total deferred	(509,000		)	(643,000		)
	Valuation allowance	509,000			643,000
	Total	$	—		$	—
Schedule of accounting for the difference between income taxes computed at the federal statutory rate and the provision for income taxes	Years Ended	March 31, 2015			March 31, 2014
	Federal statutory rate	$	(470,000	)	$	(606,000	)
	Effect of:
	State taxes, net of federal tax benefit	(48,000		)	(62,000		)
	Other	12,000			22,000
	Valuation allowance	506,000			646,000
	Total	$	—		$	—
Schedule of components of the deferred tax asset	Years Ended	March 31, 2015			March 31, 2014
	Credits and net operating loss carryforwards	$	3,936,000		$	3,067,000
	Impairment reserve	—			412,000
	Other	158,000			106,000
	Gross deferred tax assets	4,094,000			3,585,000
	Valuation allowance	(4,094,000		)	(3,585,000		)
	Total deferred tax assets	$	—		$	—

Description_of_Business_Detail

Description of Business (Details) (USD $)	Mar. 31, 2015	Mar. 31, 2014
Description of Business
Accumulated deficit	$20,340,117	$18,957,371

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
	item
Concentration of credit risk
Federally insured limit	$250,000
Number of financial institutions which maintain a majority of the entity's cash balances	1
Activity in allowance for doubtful accounts
Balance, beginning of year	8,000	9,000
Provision for estimated losses	9,582	4,042
Write-off of uncollectible accounts	-6,082	-5,042
Balance, end of year	11,500	8,000
Net accounts receivable	965,355	863,220
Warranty claims activity
Balance, beginning of year	35,000	55,000
Provision for estimated warranty claims	-15,000	-20,000
Balance, end of year	20,000	35,000
Inventories
Raw materials	1,547,733	1,498,867
Finished goods	1,029,921	1,285,361
Total gross inventories	2,577,654	2,784,228
Less reserve for obsolescence	-240,000	-560,000
Total net inventories	$2,337,654	$2,224,228
Accounts receivable | Customer concentration risk
Activity in allowance for doubtful accounts
Number of major customers	1	1
Accounts receivable | Customer concentration risk | One customer
Activity in allowance for doubtful accounts
Concentration risk (as a percent)	5.00%	5.00%
Accounts receivable | Credit concentration risk
Activity in allowance for doubtful accounts
Concentration risk (as a percent)	0.00%

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 2) (USD $)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Activity in inventory reserve for obsolescence
Provision for impairment		$456,501
Inventory reserve
Activity in inventory reserve for obsolescence
Balance, beginning of year	560,000	51,000
Provision for estimated obsolescence	135,902	106,528
Provision for impairment		456,501
Write-off of obsolete inventory	-455,902	-54,029
Balance, end of year	$240,000	$560,000

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details 3) (USD $)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Other Accrued Liabilities
Warranty	$20,000	$35,000
Sales commissions	82,132	38,065
Lease normalization	22,655	6,310
Sales and use tax	21,124	18,108
Marketing fees	8,133	10,560
Legal and audit fees	38,493	45,439
Payroll taxes	24,120	23,554
Medical device tax	7,651	8,425
Employment agreement	87,282	120,000
Trade shows		50,000
Miscellaneous	13,336	53,088
Total other accrued liabilities	324,926	408,549
Accumulated amortization	-153,494	-215,969
Total net patents and patent applications	257,356	248,971
Income Taxes
ASC 740 liability	0
Unrecognized tax benefits	0
Amount of income tax related interest or penalties assessed or recorded	0
Impact on effective tax rate due to adoption of ASC 740	0.00%
Sales Recognition
Obligations related to product sales	0
Medical Device Tax
Excise tax rate on the sale of certain medical devices (as a percent)	2.30%
Patents
Other Accrued Liabilities
Economic or legal life	20 years
Patents issued	280,669	367,217
Accumulated amortization	-153,494	-215,969
Patents issued, net of accumulated amortization	127,175	151,248
Patent applications	130,181	97,723
Total net patents and patent applications	257,356	248,971
Expected annual amortization expense related to patents and patent applications
2016	21,924
2017	21,924
2018	21,924
2019	21,924
2020 and following	169,660
Total	$257,356

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Details 4) (USD $)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Property and Equipment
Depreciation expense	$357,985	$473,867
Minimum
Property and Equipment
Estimated useful lives of assets	3 years
Maximum
Property and Equipment
Estimated useful lives of assets	7 years

Summary_of_Significant_Account7

Summary of Significant Accounting Policies (Details 5) (USD $)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
	item
Stock-Based Compensation
Stock-based compensation expense related to grants of employee stock options	$62,608	$64,518
Segment Reporting
Number of operating segments	1
Basic and Diluted Income per Common Share
Net loss	-1,382,746	-1,781,678
Weighted-average shares - basic (in shares)	10,673,225	8,921,669
Weighted-average shares - diluted (in shares)	10,673,225	8,921,669
Net loss per share-basic and diluted (in dollars per share)	($0.13)	($0.20)
Antidilutive equity units (in shares)	599,924	531,000
Cost of sales
Stock-Based Compensation
Stock-based compensation expense related to grants of employee stock options	1,965	1,381
Sales and marketing
Stock-Based Compensation
Stock-based compensation expense related to grants of employee stock options	11,076	10,420
General and administrative
Stock-Based Compensation
Stock-based compensation expense related to grants of employee stock options	46,522	44,854
Research and development
Stock-Based Compensation
Stock-based compensation expense related to grants of employee stock options	$3,045	$7,863

Shareholders_Equity_Details

Shareholders' Equity (Details) (USD $)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Additional disclosures
Stock-based compensation expense	$62,608	$64,518
Fair value of traded options, vesting restrictions	0.00%
Stock options
Assumptions for employee stock options
Risk-free interest rate, minimum (as a percent)	1.40%	0.70%
Risk-free interest rate, maximum (as a percent)	1.70%	1.70%
Expected life	5 years	5 years
Expected volatility, minimum (as a percent)	74.00%	75.00%
Expected volatility, maximum (as a percent)	75.00%	106.00%
Expected dividend (as a percent)	0.00%	0.00%
Additional disclosures
Fair value of options granted	51,000	275,000
Stock-based compensation expense		62,608	64,518
Stock option activity and related information
Granted (in shares)	95,000	405,000
Restricted Stock Units (RSUs)
Stock option activity and related information
Granted (in shares)	24,924	0
Restricted Stock Units (RSU's) activity and related information
Granted (in shares)	24,924
Balance at the end of the period (in shares)	24,924
Weighted-Average Exercise Price per Share
Granted (in dollars per share)	$0.80
Balance at the end of the period (in dollars per share)	$0.80
Plan | Stock options
Shareholders' Equity
Exercisable on each anniversary (as a percent)	20.00%
Vesting period	5 years
Exercisable period	5 years
Number of shares authorized	700,000
Total unrecognized compensation costs related to nonvested stock options	$266,000
Expected period for recognition of compensation costs related to nonvested stock options	5 years
Equity compensation plans approved by security holders | Stock options
Stock option activity and related information
Balance at the beginning of the period (in shares)	281,000	437,000
Granted (in shares)	75,000	185,000
Forfeited/expired (in shares)	-26,000	-341,000
Balance at the end of the period (in shares)	330,000	281,000
Weighted-Average Exercise Price per Share
Balance at the beginning of the period (in dollars per share)	$1.06	$1.24
Granted (in dollars per share)	$0.84	$0.99
Forfeited/expired (in dollars per share)	$1.73	$1.25
Balance at the end of the period (in dollars per share)	$0.96	$1.06
Equity compensation plans not approved by security holders | Stock options
Stock option activity and related information
Balance at the beginning of the period (in shares)	250,000	110,000
Granted (in shares)	20,000	220,000
Forfeited/expired (in shares)	-25,000	-80,000
Balance at the end of the period (in shares)	245,000	250,000
Weighted-Average Exercise Price per Share
Balance at the beginning of the period (in dollars per share)	$0.97	$1.15
Granted (in dollars per share)	$1	$0.93
Forfeited/expired (in dollars per share)	$1.12	$1.10
Balance at the end of the period (in dollars per share)	$0.96	$0.97

Shareholders_Equity_Details_2

Shareholders' Equity (Details 2) (USD $)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
STOCK OPTIONS EXERCISABLE
Common stock available for grant under the Plan (in shares)	600,076
Stock options
STOCK OPTIONS OUTSTANDING
Number Outstanding (in shares)	575,000
Weighted-Average Remaining Contractual Life	3 years 4 months 24 days
Weighted-Average Exercise Price per Share (in dollars per share)	$0.96
STOCK OPTIONS EXERCISABLE
Number Exercisable (in shares)	163,332
Weighted-Average Exercise Price per Share (in dollars per share)	$1.02
Nonqualified stock options
STOCK OPTIONS OUTSTANDING
Number Outstanding (in shares)	575,000
$0.60 - $1.09 | Stock options
Employee stock options outstanding and exercisable
Exercise price, low end of range (in dollars per share)		$0.60
Exercise price, high end of range (in dollars per share)		$0.94
STOCK OPTIONS OUTSTANDING
Number Outstanding (in shares)	345,000
Weighted-Average Remaining Contractual Life	3 years 6 months
Weighted-Average Exercise Price per Share (in dollars per share)	$0.83
STOCK OPTIONS EXERCISABLE
Number Exercisable (in shares)	69,296
Weighted-Average Exercise Price per Share (in dollars per share)	$0.79
$1.15 - $1.34 | Stock options
Employee stock options outstanding and exercisable
Exercise price, low end of range (in dollars per share)		$1
Exercise price, high end of range (in dollars per share)		$1.09
STOCK OPTIONS OUTSTANDING
Number Outstanding (in shares)	110,000
Weighted-Average Remaining Contractual Life	3 years 4 months 24 days
Weighted-Average Exercise Price per Share (in dollars per share)	$1.02
STOCK OPTIONS EXERCISABLE
Number Exercisable (in shares)	35,856
Weighted-Average Exercise Price per Share (in dollars per share)	$1.04
$1.45 - $1.90 | Stock options
Employee stock options outstanding and exercisable
Exercise price, low end of range (in dollars per share)		$1.10
Exercise price, high end of range (in dollars per share)		$1.50
STOCK OPTIONS OUTSTANDING
Number Outstanding (in shares)	120,000
Weighted-Average Remaining Contractual Life	3 years 1 month 6 days
Weighted-Average Exercise Price per Share (in dollars per share)	$1.26
STOCK OPTIONS EXERCISABLE
Number Exercisable (in shares)	58,180
Weighted-Average Exercise Price per Share (in dollars per share)	$1.28

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	12 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	29-May-15
	item
Commitments and contingencies
Leasehold improvements granted by the landlord included in lease		$172,176
Minimum future capital equipment lease payments
Less current portion		-67,057
Credit facility agreement
Number of observations under FDA inspection	5
Number of observations under FDA inspection which are believed to be material	0
Contingent severance benefit obligations	87,282
Line of credit
Credit facility agreement
Line of credit	64,000
Remaining borrowing capacity available	517,000
Line of credit | Subsequent event
Credit facility agreement
Maximum borrowing capacity			2,000,000
Term			1 year
Variable rate margin (as a percent)			1.25%
Debt Instrument Borrowing Base Ratio			2
Period of outstanding accounts payable balances excluded from the calculation of the borrowing base ratio under the terms of the debt agreement			60 days
Line of credit | Prime Rate | Subsequent event
Credit facility agreement
Variable rate margin (as a percent)			1.25%
Facilities at 6797 Winchester Circle, Boulder, Colorado
Commitments and contingencies
Currently leased area (in square feet)	28,696
Leasehold improvements granted by the landlord included in lease	172,176
Minimum future lease payments, by fiscal year
2016	268,672
2017	276,732
2018	285,034
2019	293,585
2020	99,800
Total	1,223,823
Equipment leases with General Electric Capital Corporation
Minimum future capital equipment lease payments
Capital lease remaining balance	0
Original cost of lease equipment acquired	177,547
Net book value of lease equipment acquired	$86,069

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Deferred:
Federal	($461,000)	($583,000)
State	-48,000	-60,000
Total deferred	-509,000	-643,000
Valuation allowance	509,000	643,000
Reconciliation of the income taxes computed at the federal statutory rate and the provision for income taxes
Federal statutory rate	-470,000	-606,000
Effect of:
State taxes, net of federal tax benefit	-48,000	-62,000
Other	12,000	22,000
Valuation allowance	506,000	646,000
Components of deferred tax asset
Credits and net operating loss carryforwards	3,936,000	3,067,000
Impairment reserve		412,000
Other	158,000	106,000
Gross deferred tax assets	4,094,000	3,585,000
Valuation allowance	-4,094,000	-3,585,000
Net operating loss carryovers	10,500,000
Income tax deductions related to stock options	582,000
Research and Development.
Income Taxes
Research and development tax credits	$214,000

Legal_Proceedings_Details

Legal Proceedings (Details)	12 Months Ended
	Mar. 31, 2015
	item
Legal Proceedings
Number of legal proceedings	59

Major_CustomersSuppliers_Detai

Major Customers/Suppliers (Details)	12 Months Ended
	Mar. 31, 2015
	item
Major customers/suppliers
Minimum number of hospitals from which sales were generated	350
Number of hospital customers	0
Maximum percentage of total sales contributed by a single customer	3.00%
New Deantronics, Inc.
Major customers/suppliers
Percentage of purchases accounted for by a major supplier	11.00%

Defined_Contribution_Employee_1

Defined Contribution Employee Benefit Plan (Details)	12 Months Ended
	Mar. 31, 2015
Defined Contribution Employee Benefit Plan
Minimum service period required for eligibility under the defined contribution plan	3 months
Minimum age for eligibility under the defined contribution plan	18 years
Participants contribution limit as a percentage of gross pay, maximum	20.00%
Vesting period for participants under the defined contribution plan	5 years

Related_Party_Transaction_Deta

Related Party Transaction (Details) (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2015
Related party transaction
Accrued liability under the employment agreement	$120,000		$87,282
Director
Related party transaction
Consulting fees paid	84,733	92,308
Director, one
Related party transaction
Consulting fees paid	$4,000	$89,519

Impairment_Cost_Details

Impairment Cost (Details) (USD $)	12 Months Ended
	Mar. 31, 2014
Impairment Cost.
Product impairment cost	$1,100,368
Asset Impairment Charges	643,867
Impairment of inventory	$456,501

Subsequent_Events_Details

Subsequent Events (Details) (Line of credit, USD $)	0 Months Ended
	29-May-15	Mar. 31, 2015
Subsequent Events
Line of credit		$64,000
Remaining borrowing capacity available		517,000
Subsequent event
Subsequent Events
Maximum borrowing capacity	$2,000,000
Term	1 year
Variable rate margin (as a percent)	1.25%
Borrowing base ratio	2
Period of outstanding accounts payable balances excluded from the calculation of the borrowing base ratio under the terms of the debt agreement	60 days
Subsequent event | Prime Rate
Subsequent Events
Variable rate margin (as a percent)	1.25%